We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis

By LabMedica International staff writers
Posted on 13 May 2024
Print article
Image: Scientists will evaluate new blood-based biomarkers using highly sensitive technology (Photo courtesy of 123RF)
Image: Scientists will evaluate new blood-based biomarkers using highly sensitive technology (Photo courtesy of 123RF)

Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need for a more reliable method to determine which patients should receive a CT scan and to identify those at greater risk of developing severe symptoms. Now, a new collaboration that aims to identify mild TBI earlier could help nearly 56 million patients worldwide with mild TBI benefit from a more accurate approach to diagnosis.

Danaher Corporation (Washington, D.C., USA) has entered into a collaboration with Johns Hopkins University (Baltimore, MD, USA) to develop new diagnostic methods for mild TBI. This collaboration is part of the Danaher Beacons program, where Johns Hopkins researchers will utilize technology from Beckman Coulter Diagnostics, a subsidiary of Danaher, to establish correlations between between novel biomarker panels and clinical outcomes. The Beacon builds on recent advancements in neurological biomarker research and the application of next-generation immunoassay detection technologies developed by Beckman Coulter. Should this method prove successful, it could also be adapted to diagnose other forms of brain injuries and neurodegenerative diseases.

"Our latest in vitro diagnostics innovations are improving the detection of specific biomarkers found in blood when brain cells are damaged,” said Julie Sawyer Montgomery, Vice President and Group Executive, Danaher Diagnostics. “We are thrilled to partner with Johns Hopkins with the goal of leveraging these solutions to develop tests for earlier and more precise diagnosis of mild TBI, which could ultimately lead to improved treatment outcomes and faster recovery for patients."

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: Microscopic images showing healthy villi on the left and diseased villi on the right (Photo courtesy of Florian Jaeckle/University of Cambridge)

Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy

Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.